Literature DB >> 9614352

Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function.

J F Wang1, V Milosveski, C Schramek, G H Fong, G P Becks, D J Hill.   

Abstract

Angiogenesis is an important component in the development of thyroid goitre. Vascular endothelial growth factor (VEGF) represents a family of specific endothelial cell mitogens involved in normal angiogenesis and in tumour development. The purpose of this study was to determine the distribution of VEGF in thyroid tissues during goitre formation, and to study the actions of VEGF on the regulation of thymidine incorporation and iodine uptake by thyroid follicular cells. Goitre was induced in adult rats by administration of methimazole together with a low iodine diet. Thyroid from normal or goitrous rats was removed, fixed and sectioned. Immunocytochemistry performed for VEGF using the avidin-biotin system showed that VEGF is present in normal thyroid and is located mainly in the vascular endothelium and interfollicular stromal tissue. After administration of goitrogen for 2 weeks, which caused a two- to threefold increase in thyroid weight, staining of VEGF was less apparent within the interfollicular stroma, but strongly increased throughout the thyroid follicular and endothelial cells. Uptake of [125I] and incorporation of [3H]thymidine by Fisher rat thyroid cells (FRTL-5) were measured after 72 h culture with or without TSH or VEGF, or both. In the absence of TSH, incubation with VEGF caused a significant reduction in [3H]thymidine incorporation, but did not significantly alter [125I] uptake. Incubation with TSH (1 mU/ml) caused a fourfold increase in [3H]thymidine incorporation that was diminished by co-incubation with 10 ng/ml or greater VEGF. Similarly, 10 ng/ml or greater VEGF significantly reduced the ability of TSH to increase [125I] uptake. The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum. A DNA fragment representing mRNA encoding the VEGF receptor, flt-1, was identified in FRTL-5 cells by reverse transcription PCR analysis, and the abundance of this fragment was increased in FRTL-5 cells cultured in the medium containing TSH (1 mU/ml) or fibroblast growth factor (FGF)-2 (25 ng/ml). These results indicated that VEGF and one of its receptors, Flt-1, are present in epithelial cells of the thyroid, and that VEGF could contribute to the regulation of development and function of thyroid epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614352     DOI: 10.1677/joe.0.1570005

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  17 in total

Review 1.  Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model.

Authors:  H Rubén Harach; Gustavo A Ceballos
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

2.  Sunitinib-induced thyrotoxicosis.

Authors:  D Piñar; E Boix; J A Meana; J Herrero
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

Review 3.  Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

Authors:  Sylvie Négrier; Eric Raymond
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

4.  VEGF and GM-CSF levels in nodular thyroid diseases.

Authors:  Birsen Bilgici; Gulcin C Ecemis; Ozgur K Tuncel; Ilkay K Bayrak; Elif K Kan; Aysegul Atmaca
Journal:  Endocrine       Date:  2013-04-28       Impact factor: 3.633

5.  Iodine deficiency induces a thyroid stimulating hormone-independent early phase of microvascular reshaping in the thyroid.

Authors:  Anne-Catherine Gérard; Sylvie Poncin; Bertrand Caetano; Pierre Sonveaux; Jean-Nicolas Audinot; Olivier Feron; Ides M Colin; Fabrice Soncin
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

6.  Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders.

Authors:  Asako Itoh; Katsumi Iwase; Shin Jimbo; Haruo Yamamoto; Naoki Yamamoto; Masahiro Kokubo; Takao Senda; Akira Nakai; Akio Nagagasaka; Takaaki Nagasaka; Yatsuka Hibi; Teppei Seko
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

7.  Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.

Authors:  Ala'eddin Jebreel; James England; Karen Bedford; Justin Murphy; Laszlo Karsai; Stephen Atkin
Journal:  Int J Exp Pathol       Date:  2007-08       Impact factor: 1.925

Review 8.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

9.  Expression of vascular endothelial growth factor in normal pituitary cells and pituitary adenomas producing adrenocorticotropic hormone.

Authors:  T Yamamoto; Y Nishizawa; M Tsuji; Y Saitoh; H Funai; T Hirai; A Sugihara; T Tsujimura; Y Nakata; S Ishiguro; N Terada
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

10.  THE CORRELATION BETWEEN INFLAMMATORY AND METABOLIC PARAMETERS WITH THYROID FUNCTION IN PATIENTS WITH HASHIMOTO'S THYROIDITIS: THE POTENTIAL ROLE OF INTERLEUKIN 23 (IL-23) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) - 1.

Authors:  M Abbasalizad Farhangi; S Tajmiri
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Apr-Jun       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.